Logo

Texas VA Hospital Buys Cepheid’s Xpert MRSA Kit

May 04, 2007
NEW YORK (GenomeWeb News) — A Veterans Affairs hospital in Houston has bought a Cepheid test that detects antibiotic-resistant staphylococcus bacteria, the company said today.
 
Cepheid said the Michael E. DeBakey VA Medical Center has bought its GeneXpert MRSA kit, which tests for methicillin-resistant staphylococcus, the most common cause of nosocomial infections.
 
The MRSA also is resistant to oxacillin, penicillin, and amoxicillin, and affects those with weakened immune systems.
 
The MRSA test runs on Cepheid’s GeneXpert System, and can produce results in “just over an hour,” the company said.
 
The US Food and Drug Administration cleared the Xpert MRSA test on April 18.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.